Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.795 USD | +5.59% | +1.45% | +203.48% |
01:46pm | Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study | MT |
May. 14 | Transcript : Ocugen, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+203.48% | 437M | |
+26.75% | 49.18B | |
+0.57% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+12.49% | 26.09B | |
-21.95% | 18.71B | |
+9.17% | 13.26B | |
+30.83% | 12.32B | |
-0.57% | 11.99B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Ocugen Says Mucosal Vaccine Candidate Selected for Clinical Trials by US NIAID